CTRI/2018/06/014519已完成未知
A Randomized, Double blind, Multicenter, Three-arm, Parallel, Placebo-controlled, Clinical Study to Evaluate the Bioequivalence using Clinical Endpoint of Diclofenac Sodium Topical Gel, 1% (Encube Ethicals Private Limited, India) to Voltaren Gel (Diclofenac Sodium Topical Gel) 1% (Endo Pharmaceuticals Inc., USA) in Subjects with Osteoarthritis (OA) of the Knee.
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 1,116
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Healthy male or non-pregnant female aged more than to equal to 35 years with a clinical diagnosis of OA of the knee according to the American College of Rheumatology (ACR) criteria2 i.e. Knee pain along with at least 3 of the following 6 criteria
- •a.Age > 50 years
- •b.Stiffness less than 30 minutes
- •c.Presence of crepitus
- •d.Bony tenderness
- •e.Bony enlargement
- •f.No palpable warmth
- •2.Symptoms in target knee for at least 6 months prior to screening
- •3.Knee (not referred) pain in target knee for 15 days of the preceding month (periarticular knee pain due to OA and not due to other conditions such as bursitis, tendonitis, etc.)
- •4.Pain in the target knee requiring the use of NSAIDs or acetaminophen (paracetamol) (topical or oral treatments).
- •5.Subject having an X-ray of the target knee, taken no more than 1 year before baseline, showing evidence of OA with Kellgren-Lawrence grade 1-3 disease.
- •6.After discontinuing all pain medications (placebo run â?? in period) for at least 7 days, has at least moderate pain on movement (POM) for target knee, defined as a baseline score of more than or equal to 50 mm on a 0-100 mm Visual Analog Scale (VAS) immediately prior to randomization.
- •7.After discontinuing all pain medications (placebo run â?? in period) for at least 7 days has a baseline Western and Ontario McMaster Universities Osteoarthritis Index (WOMAC Likert) pain subscale of more than or equal to 9 immediately prior to randomization.
- •8.Able to tolerate rescue medication with only acetaminophen (paracetamol) taken as l-2 tablets up to a maximum of 2 gm per day for the duration of the study.
- •9.Subjects who can read and understand WOMAC pain sub scale.
- •10.Able to give written informed consent to participate in the study.
- •11.Male subjects and Female subjects of childbearing potential agree to use accepted methods of birth control including abstinence, from study start to 7 days after the last application of study drug.
排除标准
- •1.Pregnant or lactating or planning to become pregnant during the study period.
- •2.X-ray showing evidence of OA with Kellgren-Lawrence grade 4 disease.
- •3.History of OA pain in the contralateral knee requiring medication (OTC or prescription) within 1 year prior to screening.
- •4.After discontinuing all pain medications (placebo run-in period)for at least 7 days, had a baseline score of more than or equal to 20 mm on a 0-100 mm Visual Analog Scale (VAS) for the contralateral knee immediately prior to randomization.
- •5.History of OA of either Hip or Hands.
- •6.History of secondary OA (e.g. congenital, traumatic, gouty arthritis) or rheumatoid arthritis.
- •7.History of chronic inflammatory disease (e.g., colitis) or fibromyalgia.
- •8.History of drugs or alcohol abuse with in the previous year.
- •9.Symptomatic peripheral vascular disease of the study leg (prior or current).
- •10.Any musculoskeletal condition that would impede measurement of efficacy at the target knee.
- •11.History of regular headaches or backache which warrants frequent use of acetaminophen (paracetamol) or NSAIDs within the previous year.
- •12.Concomitant skin disease at the application site which may affect study drug application or tolerability evaluation.
- •13.History of active asthma within the previous year that may require periodic treatment with systemic steroids during the study period (note: inhaled steroids for this condition are allowed).
- •14.History of aspirin sensitive asthma.
- •15.History of uncontrolled hypertension (blood pressure more than 150/100 mm of Hg) in spite of treatment with in the previous year and/or any other clinically significant vital sign abnormality.
- •16.History of uncontrolled diabetes mellitus (HbA1C greater than 8 percent).
- •17.Subjects with BMI more than 40 kg/m2.
- •18.History of myocardial infarction, thrombotic events, stroke, congestive heart failure, impaired renal function (Serum creatinine greater than 1.5 x ULN), or liver disease with in the previous year.
- •19.History of coronary artery bypass graft within 6 months of screening.
- •20.History of gastrointestinal bleeding or peptic ulcer disease in last one year.
- •21.Known allergy to aspirin, nonsteroidal anti-inflammatory drugs (NSAID) or acetaminophen (paracetamol).
- •22.Elevated transaminases (greater than or equal to 3 times ULN) and hemoglobin less than 9.0 g/dL at screening.
- •23.Viscosupplementation in any joint including the target knee within 6 months prior to screening.
- •24.Use of anticoagulants, ACE-inhibitors, cyclosporine, diuretics, lithium, or methotrexate prior to 30 days of screening.
- •25.Concomitant use of intra articular corticosteroids, systemic corticosteroids, topical corticosteroids, or immunosuppressive drugs or their use prior to 30 days of screening.
- •26.Concomitant acetylsalicylic acid therapy other than a stable low dose used for cardiac prophylaxis (maximum 162 mg daily)3 taken for at least 3 months prior to enrollment and maintained throughout the duration of the study.
- •27.History of major surgery or previous damage to the study knee at any time, or minor knee surgery (e.g. any surgery other than major surgery including, but not limited to, cartilage repair, collateral ligament repair, or arthroscopic debridement) to the study knee within 1 year prior to screening.
- •28.Known history of positive HIV, HC
研究者
相似试验
已完成
不适用
Clinical study to compare efficay of two formulations of Clindamycin Phosphate 1.2% and Benzoyl Peroxide 5% Gel in patients with Acne VulgarisCTRI/2018/06/014684Encube Ethicals Private Limited
已完成
不适用
Compare the Efficacy and Safety of Mupirocin Cream USP, 2% in patients with Secondarily Infected Traumatic Skin LesionsCTRI/2020/08/027198Ms Cadila Healthcare Limited956
尚未招募
不适用
This study is conducted to know the effectiveness of Adapalene 0.1% gel on patients having mild, moderate and severe pimples and to know how such patients will tolerate the medicine and how safe it is in these patients.CTRI/2020/11/028831THINQ PharmaCRO Private Limited
已完成
不适用
Comparison of Tretinoin Cream 0.10% from Encube Ethicals Pvt. India Ltd with RETIN-A (Tretinoin) Cream, 0.10% (Bausch Health US, LLC Bridgewater, NJ 08807 USA) and placebo in the treatment of acne vulgaris.CTRI/2022/11/047270Encube Ethicals Private Limited610
已完成
不适用
Comparison of Tretinoin Cream 0.025% from Cadila Healthcare Limited with RETIN-A (Tretinoin) Cream, 0.025% (Valeant Pharmaceuticals North America LLC., USA) and placebo in the treatment of acne vulgarisCTRI/2022/04/042178Cadila Healthcare Limited715